share_log

Altamira Therapeutics | UPLOAD: Others

SEC announcement ·  Jan 17 00:41
Summary by Futu AI
Altamira Therapeutics Ltd., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-3, filed on January 8, 2024, will not undergo review. The SEC's communication, dated January 16, 2024, was addressed to Thomas Meyer, CEO of Altamira Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tamika Sheppard.
Altamira Therapeutics Ltd., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-3, filed on January 8, 2024, will not undergo review. The SEC's communication, dated January 16, 2024, was addressed to Thomas Meyer, CEO of Altamira Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tamika Sheppard.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.